Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WALTHAM, Mass.--( BUSINESS WIRE )--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 10:30 a.m. (EST).

Thermo Fisher Scientific to Present at Evercore ISI HealthCONx Conference

Pfizer

Vertex Pharmaceuticals

These businesses are built for the long run.

3 Unstoppable Growth Stocks to Buy and Hold

CARLSBAD, Calif.--( BUSINESS WIRE )--Thermo Fisher Scientific, the world leader in serving science, today introduced the Gibco CTS AAV-MAX Helper-Free AAV Production System, a new all-in-one solution designed to help meet clinical and commercial demands for cost-effective and scalable development of adeno-associated virus (AAV)-based gene therapies. To date, it is the only product of its kind that is manufactured under cGMP conditions to enable large-scale applications.

Thermo Fisher Scientific Introduces All-in-One AAV Production System for Scalable Gene Therapy Workflows and Commercial Applications

WALTHAM, Mass.--( BUSINESS WIRE )--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that on November 14, 2022 it priced an offering of €1.25 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes:

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

Accenture Plc

Automatic Data Processing

Applied Materials

Amphenol

Bank of New York Mellon

Blackrock Inc

Costco

Graco

Home Depot

Lockheed Martin

Lowe's

Mastercard

Microsoft

Northrop Grumman

Roper Technologies

Sherwin-Williams

Texas Instruments

U.S. Bancorp

Vanguard Dividend Appreciation ETF

There are 19 stocks on my dividend growth watchlist for November 2022. The majority of the stocks on my watchlist for this month are currently undervalued based on dividend yield theory.

Dividend Growth Stock Watchlist - November 2022

Thermo Fisher Scientific and Society for Science Launch Junior Innovators Challenge to Inspire More Than 65,000 Future STEM Leaders Nationwide

FRANKFURT, Germany--(BUSINESS WIRE)--This week at CPHI Frankfurt, Thermo Fisher Scientific will showcase its expertise, innovations and capabilities to help pharmaceutical and emerging biotech companies accelerate time to market across a wide range of modalities and platforms, including cell and gene therapies, oral solids, steriles and biologics.

Thermo Fisher Scientific Showcases Pharma Services Innovation and Expertise at CPHI Frankfurt 2022

Binding Site builds medical instruments that help diagnose blood cancers and immune system disorders.

Thermo Fisher Makes Another Acquisition. Spends $2.6 Billion on Testing Company.

Thermo Fisher Scientific Continues to Execute Proven Capital Deployment Strategy

Thermo Fisher Scientific to Acquire The Binding Site Group

Thermo Fisher Scientific to Showcase New Innovative Laboratory Solutions at AMP 2022

Thermo Fisher Scientific to Expand Clinical Research Laboratory in Kentucky

Thermo Fisher's sales and earnings headwinds from declining Covid testing is finally nearing an end. The core business outside of Covid is growing at 14% organically this year and the long-term plan of 7-9% growth looks achievable.

Thermo Fisher Scientific: Back To Normal

Robust demand for Thermo Fisher's (TMO) laboratory products and biopharma services buoys optimism. However, lower Life Sciences Solutions segment revenues in the third quarter disappoint.

Thermo Fisher (TMO) Q3 Earnings Top Estimates, Margins Down

Thermo Fisher Scientific Inc. (NYSE:TMO ) Q3 2022 Earnings Conference Call October 26, 2022 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President and Chief Executive Officer Stephen Williamson - Senior Vice President and Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Derik De Bruin - Bank of America Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Dan Brennan - Cowen Rachel Vatnsdal - JPMorgan Dan Arias - Stifel Tejas Savant - Morgan Stanley Operator Good morning, ladies and gentlemen and welcome to the Thermo Fisher Scientific 2022 Third Quarter Conference Call. [Operator Instructions] I would like to introduce our moderator for the call, Mr.

Thermo Fisher Scientific Inc. (TMO) Q3 2022 Earnings Call Transcript

Thermo Fisher Scientific Reports Third Quarter 2022 Results

LAS VEGAS--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will demonstrate the benefits of collaborating to advance the science of transplantation and connecting breakthroughs to patients this week at the 48th Annual Meeting of the American Society for Histocompatibility & Immunogenetics (ASHI) Conference in Las Vegas.

Thermo Fisher Scientific demonstrates commitment to transplant patients and collaboration at ASHI 2022

ASML Hld

Alphabet

Look past all the noise and think about the bigger picture.

Buying These 3 Stocks Could Be the Smartest Move You Ever Make

Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Thermo Fisher (TMO) Could Beat Earnings Estimates Again

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been awarded the Eagle Award for the second consecutive year for its outstanding leadership, professionalism, integrity and dedication to advancing the clinical research profession through strong partnerships with research sites.

Thermo Fisher Scientific Named 2022 Eagle Award Winner for Clinical Research Site Partnerships

Thermo Fisher Scientific Launches Closed and Automated Cell Isolation and Bead Removal Solution to Help Evolve Cell Therapy Manufacturing

Thermo Fisher Scientific Prices Offering of Yen-Denominated Senior Notes

Thermo Fisher Scientific, the world leader in serving science, today expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia. The new unit will support increasing demand across biopharma for consistent, high-quality laboratory services to accelerate drug development. The 59,000-square-foot facility is part of the previously announced $97 million investment by the company to expand its bioanalytical laboratory operations in Richmond and add more than 500 jobs over the next three years.

Thermo Fisher Scientific Unveils New Clinical Research Laboratory in Virginia

This panel of Thermo Fisher (TMO), apart from detecting GI bacteria, also helps in identifying the root cause of an infection and administering the best suitable treatment fast.

Thermo Fisher (TMO) Launches New TaqPath Panel in Europe

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TaqPath Enteric Bacterial Select Panel, a CE-IVD marked panel designed to detect common gastrointestinal (GI) bacteria and help enable clinicians to identify the root cause of an infection and administer the most appropriate treatment to their patients more quickly. The panel was validated and registered under IVDD in May 2022. The new test leverages polymerase cha

Thermo Fisher Scientific Launches CE-IVD Marked Panel to Detect Most Common Gastrointestinal Bacteria

News for Thermo Fisher Scientific Stock (TMO)